+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Placenta Growth Factor - Pipeline Review, H2 2019

  • ID: 4900271
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 89 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alteogen Inc
  • Cinnagen Co
  • Formycon AG
  • i2 Pharmaceuticals Inc
  • Luye Pharma Group Ltd
  • PharmAbcine Inc
  • MORE
Placenta Growth Factor - Pipeline Review, H2 2019

Summary

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 19 molecules. The latest report Placenta Growth Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 2, 5 and 5 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Choroidal Neovascularization, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Ewing Sarcoma, Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT), Medulloblastoma, Metastatic Colorectal Cancer, Myopia, Neovascular Glaucoma, Neuroblastoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinopathy, Retinopathy Of Prematurity, Rhabdomyosarcoma and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alteogen Inc
  • Cinnagen Co
  • Formycon AG
  • i2 Pharmaceuticals Inc
  • Luye Pharma Group Ltd
  • PharmAbcine Inc
  • MORE
Introduction
Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Benitec Biopharma Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cinnagen Co
Coherus BioSciences Inc
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Lupin Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
Oxurion NV
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Shandong Boan Biological Technology Co Ltd
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Sep 02, 2019: Oxurion to present on its Diabetic Macular Edema drug candidate THR-317 at EURETINA 2019
Aug 22, 2019: Oxurion reports mixed results from Phase IIa DME study
Aug 13, 2019: Last trial OKed for Eylea to prevent blindness in premature infants
Aug 13, 2019: FDA approves Eylea (AFLIBERCEPT) prefilled syringe
Jun 21, 2019: Bayer initiates phase III trial of Aflibercept to prevent blindness in premature infants
Jun 06, 2019: Oxurion - Data from a phase 1/2 clinical study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
May 22, 2019: Alteogen obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
May 13, 2019: Formycon provides update on FYB203
May 13, 2019: FDA Approves EYLEA (aflibercept) Injection for Diabetic Retinopathy
Apr 30, 2019: Watchful waiting reasonable for patients with Diabetic Macular Edema and good vision
Apr 04, 2019: Oxurion announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule
Apr 02, 2019: LY09004 approved for clinical trials in China, Luye Pharma steps-up Global R&D Investment in Biopharma Medicines
Feb 28, 2019: Alteogen applies for P1 trial for Eylea biosimilar
Feb 09, 2019: One-year results from positive phase 3 EYLEA trial in diabetic retinopathy presented at Angiogenesis Symposium
Jan 21, 2019: New anti-VEGF agent shows promising durability
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alteogen Inc, H2 2019
Pipeline by Benitec Biopharma Ltd, H2 2019
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2019
Pipeline by Cinnagen Co, H2 2019
Pipeline by Coherus BioSciences Inc, H2 2019
Pipeline by Formycon AG, H2 2019
Pipeline by Gene Techno Science Co Ltd, H2 2019
Pipeline by Huons Global Co Ltd, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by Lupin Ltd, H2 2019
Pipeline by Luye Pharma Group Ltd, H2 2019
Pipeline by Momenta Pharmaceuticals Inc, H2 2019
Pipeline by Oxurion NV, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by Samsung Bioepis Co Ltd, H2 2019
Pipeline by Shandong Boan Biological Technology Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alteogen Inc
  • Benitec Biopharma Ltd
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Cinnagen Co
  • Coherus BioSciences Inc
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • i2 Pharmaceuticals Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • Oxurion NV
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Shandong Boan Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll